# Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)

> **NCT01843998** · PHASE2 · WITHDRAWN · sponsor: **Stefan Schieke MD**

## Conditions studied

- Cutaneous T-cell Lymphoma (CTCL)

## Interventions

- **DRUG:** Sirolimus 0.1% Ointment

## Key facts

- **NCT ID:** NCT01843998
- **Lead sponsor:** Stefan Schieke MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-02
- **Primary completion:** 2015-05
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01843998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01843998, "Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01843998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*